Clinical trials: Bladder Cancers
Metastatic Cancer, Melanoma Cancer
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy…
- Conditions
- Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer
- Trial name
- NCT03693014
- Testing
- Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
This phase II trial studies how well autologous tumor infiltrating lymphocytes (LN-145) and pembrolizumab work in treating patients with transitional cell cancer that cannot be removed by surgery or has spread to other places in…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03935347
- Testing
- Cyclophosphamide, Fludarabine, Fludarabine Phosphate
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Bladder Cancer
Biomarker Discovery and Application in Bladder Cancer
The investigators' long-term objective is to research and develop innovative new tests which diagnostic laboratories can use to 1) detect methylated DNA targets, 2) tumor specific antigens, and 3) markers of Bacillus…
- Trial name
- NCT00962052
- Where
- Israel
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Wolfson Medical Center
Bladder Carcinoma
EHR Integrated Remote Patient Monitoring to Reduce Readmission for Patients With Bladder Cancer Undergoing Cystectomy
This clinical trial tests the feasibility of an electronic health record (EHR) integrated remote patient monitoring intervention to reduce readmission for patients with bladder cancer undergoing cystectomy.
- Trial name
- NCT07912034
- Testing
- Best Practice, Communication Intervention, Interview
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, Transitional Cell Carcinoma
Alisertib in Chemotherapy-pretreated Urothelial Cancer
Background: Progress in developing new effective therapies in advanced and relapsing urothelial cancer has been stagnant in the last few decades and a paradigm shift is desperately needed.
- Trial name
- NCT02109328
- Testing
- Alisertib, Paclitaxel
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Superficial Bladder Cancer
Evaluation of a Patient-Reported Symptom Index for NMIBC
This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects.
- Trial name
- NCT03091764
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 498 people
- Sponsor
- University of Sydney
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Bladder Cancer
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.
- Trial name
- NCT00645593
- Testing
- Gemcitabine,, Cisplatin, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, Spinal Cord Injury
Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals
Bladder cancer is a well-recognized complication in spinal cord injury (SCI) individuals. The observed incidence rates in SCI individuals are considerably higher compared to the general population.
- Trial name
- NCT02538809
- Testing
- measurement of tumor mRNA concentration in urine
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Swiss Paraplegic Research, Nottwil
Bladder Cancer, Complications
The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer
Complications after radical cystectomy for bladder cancer range from 30-40%, many of which are related to bowel function. Patients usually wait to eat until return of bowel function, although there is evidence that after primary…
- Trial name
- NCT01489800
- Testing
- Clear liquid diet
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- Columbia University
Non-muscle Invasive Bladder Cancer
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
- Trial name
- NCT02138734
- Testing
- BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
- Where
- 108 sites in United States, India and 1 more
- Volunteers
- 369 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and decrease the need for surgery.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00045630
- Testing
- carboplatin, gemcitabine, paclitaxel
- Where
- 128 sites in United States
- Volunteers
- 77 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, CIS
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine…
- Trial name
- NCT01314664
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Bladder Cancer, Bladder Cancer Stage I
The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy
The World Health Organization 2016 bladder tumor classification reported that the diagnosis of variant histology has increased from 6% to 33% in the last 2 decades, and there is an increasing interest in investigating the effects…
- Conditions
- Bladder Cancer, Bladder Cancer Stage I, Bladder Cancer Stage II
- Trial name
- NCT06358599
- Testing
- Cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 221 people
- Sponsor
- Ankara Etlik City Hospital
Bladder Cancer
Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors
Biological behabiour of low grade bladder cancer tumors is well known. They have a very high rate of recurrences during their follow up but very low (less than 1%) risk of progression.
- Trial name
- NCT05148728
- Testing
- Endoscopic fulguration
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Vall Hebron Insitut Recerca
Muscle-Invasive Bladder Carcinoma
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal…
- Trial name
- ARTIA-Vesica (NCT05295992)
- Testing
- Varian Ethos Adaptive Radiation Therapy
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Varian, a Siemens Healthineers Company
Bladder Tumors
Laser Treatment of Bladder Tumors in the Outpatient Department
Primary Objective: To show that small pTa bladder tumors can be removed with diode laser in an outpatient department. Secondary Objective: To evaluate the patients' symptoms during and after the laser TURBT.
- Trial name
- NCT02659332
- Testing
- TURBT
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Gregers G Hermann
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris
Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying, Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter
Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
Millions of patients of all ages suffer worldwide from diverse urinary pathologies, such as lower urinary tract (LUT) dysfunction, bladder pain syndrome, urinary tract infections (UTIs), or bladder cancer.
- Conditions
- Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying, Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter, Recurrent Non-catheter Associated UTIs, Acute Catheter-associated UTI (CAUTI)
- Trial name
- MiLUT (NCT07494864)
- Where
- Switzerland
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.